DEST Insider Trading (Destiny Pharma)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £251,580
Insider Selling (Last 12 Months): GBX 0
Destiny Pharma Share Price & Price History
Current Price: GBX 40
Price Change: +0.30 (1.20%)
As of 08/12/2022 01:00 AM ET
The Safest Option in Trades!
From Tradewins | Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Destiny Pharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/27/2021 | Nick Rodgers | Insider | Buy | 2,100 | £119.80 | £251,580 | | |
| 4/29/2021 | Nick Rodgers | Insider | Buy | 1,511 | GBX 149 | £2,251.39 | | |
| 4/22/2021 | Nick Rodgers | Insider | Buy | 5,000 | GBX 158 | £7,900 | | |
| 1/6/2021 | Nick Rodgers | Insider | Buy | 9,000 | GBX 88 | £7,920 | | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
SEC Filings (Institutional Ownership Changes) for Destiny Pharma (LON:DEST)
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More on Destiny Pharma
Today's Range
Now: GBX 40
50 Day Range
MA: GBX 40.98
52 Week Range
Now: GBX 40
Volume
120,794 shs
Average Volume
45,702 shs
Market Capitalization
£29.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Destiny Pharma?
